The return of the bad wolf

“There are a number of efforts to genetically change mosquitoes so that they have mass extinction so that they cannot lead certain diseases such as dengue or malaria,” he says. “I am worried that we lose control of some of these efforts because mosquitoes – although they have diseases that are bad for people – visit niche in ecology by eating certain types of birds.”

There are precedent for this type of genetic hegemony beyond the sugar cane toad. Asian Karpfen, which was introduced by the aquaculture industry to the USA in the 1970s, overwhelm the large lakes and displace different types. Burmese Pythons, which were imported into the USA as exotic pets, have established an invasive niche in Everglades, which was published there by owners who are fed up with taking care of them.

Nevertheless, colossal scientists are pushing ahead, and the company is already flourishing in an adaptive niche – not only as a scientific company, but as an impressive business. It has achieved a decacorn status worth 10.2 billion US dollars, and although it may not be easy to monetize a mammoth or a dodo or a bad wolf puppy, Lamb sees a lot of commercial potential in the technologies that its scientific team develops. Colossal has been eliminated two new companies so far. One that is referred to as breaking uses technical microbes and enzymes to reduce plastic waste. The other form organic organic, offers AI and computer biology platforms for drug development. And none of this touches colossal core competence in cell and genetic engineering, which has countless applications in the biomated area, including the treatment and prevention of diseases. “These genome engineering technologies alone are worth tens of billions of dollars,” says Lamm.